[How I treat non-Hodgkin's lymphoma by autologous hematopoietic stem cell transplantation].
作者信息
Zhang X
机构信息
Department of Hematology, Xinqiao Hospital, The Army Medical University, Chongqing 400037, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2018 Feb 14;39(2):94-97. doi: 10.3760/cma.j.issn.0253-2727.2018.02.003.
Abstract
摘要
相似文献
1
[How I treat non-Hodgkin's lymphoma by autologous hematopoietic stem cell transplantation].
Zhonghua Xue Ye Xue Za Zhi. 2018 Feb 14;39(2):94-97. doi: 10.3760/cma.j.issn.0253-2727.2018.02.003.
2
3
Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma.
Rev Bras Hematol Hemoter. 2011;33(1):10-4. doi: 10.5581/1516-8484.20110007.
4
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.
5
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Haematologica. 2013 Feb;98(2):172-8. doi: 10.3324/haematol.2012.071456. Epub 2012 Sep 14.
6
Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas.
Blood. 1990 Jul 15;76(2):424-31.
7
Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas.
Rev Bras Hematol Hemoter. 2011;33(6):432-8. doi: 10.5581/1516-8484.20110118.
8
Catheter-related thrombosis in patients with refractory lymphoma undergoing autologous stem cell transplantation.
Bone Marrow Transplant. 1991 Mar;7(3):235-40.
9
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Leuk Lymphoma. 2001 Feb;40(5-6):499-509. doi: 10.3109/10428190109097649.
10
Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
J Clin Oncol. 1995 Apr;13(4):969-73. doi: 10.1200/JCO.1995.13.4.969.
本文引用的文献
1
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Am J Hematol. 2020 Jul;95(7):775-783. doi: 10.1002/ajh.25818. Epub 2020 Apr 22.
2
Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055-2063.
Blood. 2016 Jul 21;128(3):463. doi: 10.1182/blood-2016-06-721902.
3
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
N Engl J Med. 2017 Sep 28;377(13):1250-1260. doi: 10.1056/NEJMoa1701769.
4
The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era.
Mediterr J Hematol Infect Dis. 2016 Sep 1;8(1):e2016045. doi: 10.4084/MJHID.2016.045. eCollection 2016.
5
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Cancer Sci. 2016 Dec;107(12):1785-1790. doi: 10.1111/cas.13076. Epub 2016 Nov 25.
6
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.
J Clin Oncol. 2015 Aug 10;33(23):2516-22. doi: 10.1200/JCO.2014.59.7534. Epub 2015 Jun 29.
7
[Standards for the diagnosis and treatment of malignant lymphoma (2015 version) in China].
Zhonghua Zhong Liu Za Zhi. 2015 Feb;37(2):148-58.
8
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Biol Blood Marrow Transplant. 2015 Jun;21(6):1046-1053. doi: 10.1016/j.bbmt.2015.02.005. Epub 2015 Feb 14.
9
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
J Clin Oncol. 2013 Oct 10;31(29):3688-95. doi: 10.1200/JCO.2013.49.2835. Epub 2013 Sep 3.
10
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
J Clin Oncol. 2013 May 1;31(13):1624-30. doi: 10.1200/JCO.2012.47.1862. Epub 2013 Apr 1.
Zotero 插件